These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28964882)

  • 21. [Pharmacokinetics of antibiotics in obese and critical care patients].
    Stahlmann R; Lode H
    Dtsch Med Wochenschr; 2015 Feb; 140(4):271-6. PubMed ID: 25704524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug kinetics in burn patients.
    Sawchuk RJ; Rector TS
    Clin Pharmacokinet; 1980; 5(6):548-56. PubMed ID: 7002419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vecuronium pharmacokinetics in patients with major burns.
    Vega-Villa KR; Kaneda K; Yamashita S; Woo S; Han TH
    Br J Anaesth; 2014 Feb; 112(2):304-10. PubMed ID: 24067332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
    Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
    J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational Selection and Use of Antimicrobials in Patients with Burn Injuries.
    Hill DM; Sinclair SE; Hickerson WL
    Clin Plast Surg; 2017 Jul; 44(3):521-534. PubMed ID: 28576241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unbound cephalothin pharmacokinetics in adult burn patients are related to the elapsed time after injury.
    Dalley AJ; Deans R; Lipman J; Venkatesh B; Rudd M; Roberts MS; Cross SE
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5303-5. PubMed ID: 19752272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill.
    Tsai D; Lipman J; Roberts JA
    Curr Opin Crit Care; 2015 Oct; 21(5):412-20. PubMed ID: 26348420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of tobramycin pharmacokinetics in burn patients to evaluate the potential utility of once-daily dosing in this population.
    Vella D; Walker SA; Walker SE; Daneman N; Simor A
    J Burn Care Res; 2014; 35(4):e240-9. PubMed ID: 24043237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics in patients with burns.
    Jaehde U; Sörgel F
    Clin Pharmacokinet; 1995 Jul; 29(1):15-28. PubMed ID: 7586895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?
    Jamal JA; Mueller BA; Choi GY; Lipman J; Roberts JA
    Diagn Microbiol Infect Dis; 2015 May; 82(1):92-103. PubMed ID: 25698632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.
    Roberts JA; Lipman J
    Clin Pharmacokinet; 2006; 45(8):755-73. PubMed ID: 16884316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
    Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Roger C; Udy AA; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of dosing regimens and dosing in special populations.
    Sime FB; Roberts MS; Roberts JA
    Clin Microbiol Infect; 2015 Oct; 21(10):886-93. PubMed ID: 25980350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of ceftazidime in burn patients.
    Dailly E; Pannier M; Jolliet P; Bourin M
    Br J Clin Pharmacol; 2003 Dec; 56(6):629-34. PubMed ID: 14616422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis.
    Hallam MJ; Allen JM; James SE; Donaldson PM; Davies JG; Hanlon GW; Dheansa BS
    J Burn Care Res; 2010; 31(1):207-9. PubMed ID: 20061858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiology and pharmacokinetics following burn injury.
    Bonate PL
    Clin Pharmacokinet; 1990 Feb; 18(2):118-30. PubMed ID: 2180612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients.
    Carlier M; Noë M; De Waele JJ; Stove V; Verstraete AG; Lipman J; Roberts JA
    J Antimicrob Chemother; 2013 Nov; 68(11):2600-8. PubMed ID: 23800901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.